| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California 91010-3000 [B-S. Z., B-C. P., J. H. D., Y. Y.], and Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan [N-Y. H.]
Ribonucleotide reductase (RR) is a rate-limiting enzyme in DNA synthesis. The enzyme consists of two subunits, M1 and M2. Hydroxyurea (HU) is an M2-specific inhibitor. It has been shown that a HU-resistant clone derived from stepwise exposure to HU overexpresses the M2 mRNA and the RR protein (Y. Yen et al., Cancer Res., 54: 3868–3691, 1994). In this study, we established stable clones by transfecting human KB cells with the cDNA of human wild-type RR in which each subunit was over-expressed by a SV40 promoter. The mammalian cell expression vector pHß APr-1 was used for constructing M1, M2, and M1/M2 subunit cDNA. The transfected cells were selected with G418. The clones designated M2-D, M1-D, X-D, and KB-V represent transfectant clones which contain M2 cDNA, M1 cDNA, M1/M2 cDNA, and vector alone, respectively. The parental KB cells and clones containing vector plasmid KB-V express equally low amounts of M2 and M1 mRNA from the endogenous genes. The expression of M2 mRNA and M1 mRNA is elevated 2-3-fold in the X-D transfectants. M2-D clone demonstrated a 6-fold higher M2 mRNA level although the M1 mRNA expression remains the same as parental cells. M1-D transfectants have a 3-fold increase in M1 mRNA expression relative to parental cells, but reveal no alteration of M2 mRNA. Southern analysis of genomic DNA suggested the incorporation of the plasmid into the genome. The X-D clone revealed both integration of the M2 and M1 gene while the M2-D clone only showed M2 gene integration. The M1-D clone revealed M1 gene integration relative to the parental cells. The Western blot of M2 protein showed a 3-fold increase in the X-D and M2-D clones whereas the M2 protein level in M1-D was the same as it was in parental cells. The M1 protein was increased 3-fold in X-D and 1.5-fold in M1-D over that of parental cells. However, lower M1 protein levels were identified in the M2-D clone. The specific activity of the RR enzyme from each transfectant showed a 3-fold increase in both the X-D and M2-D clones and slightly increased in M1-D clone over that of parental cells. However, X-D and M2-D both demonstrated a 3-fold increase in resistance to HU as compared to M1-D which showed the same sensitivity as the parental enzyme. From these results, we propose that the "enzymatic" activity and the resistance of RR to HU are greatly affected by the amount of the M2 subunit in the cell. These transfectants will be utilized for obtaining detailed information regarding the RR enzyme.
1 To whom requests for reprints should be addressed, at Department of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, California 91010-3000.
Received 12/27/94. Accepted 1/17/95.
This article has been cited by other articles:
|
|
 |
|
  R. B. Klisovic, W. Blum, X. Wei, S. Liu, Z. Liu, Z. Xie, T. Vukosavljevic, C. Kefauver, L. Huynh, J. Pang, et al. Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia Clin. Cancer Res., June 15, 2008; 14(12): 3889 - 3895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Jordheim, O. Guittet, M. Lepoivre, C. M. Galmarini, and C. Dumontet Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells Mol. Cancer Ther., August 1, 2005; 4(8): 1268 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Dong, Y. Liu, and J.-T. Zhang Regulation of ribonucleotide reductase M2 expression by the upstream AUGs Nucleic Acids Res., May 11, 2005; 33(8): 2715 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shao, B. Zhou, L. Zhu, W. Qiu, Y.-C. Yuan, B. Xi, and Y. Yen In Vitro Characterization of Enzymatic Properties and Inhibition of the p53R2 Subunit of Human Ribonucleotide Reductase Cancer Res., January 1, 2004; 64(1): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yen Ribonucleotide Reductase Subunit One as Gene Therapy Target: Commentary re: M-Y. Cao et al., Adenovirus-mediated Ribonucleotide Reductase R1 Gene Therapy of Human Colon Adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003. Clin. Cancer Res., October 1, 2003; 9(12): 4304 - 4308. [Full Text] [PDF]
|
|
|
|
|
|
M.-Y. Cao, Y. Lee, N.-P. Feng, K. Xiong, H. Jin, M. Wang, A. Vassilakos, S. Viau, J. A. Wright, and A. H. Young Adenovirus-Mediated Ribonucleotide Reductase R1 Gene Therapy of Human Colon Adenocarcinoma Clin. Cancer Res., October 1, 2003; 9(12): 4553 - 4561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lee, A. Vassilakos, N. Feng, V. Lam, H. Xie, M. Wang, H. Jin, K. Xiong, C. Liu, J. Wright, et al. GTI-2040, an Antisense Agent Targeting the Small Subunit Component (R2) of Human Ribonucleotide Reductase, Shows Potent Antitumor Activity against a Variety of Tumors Cancer Res., June 1, 2003; 63(11): 2802 - 2811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Md. R. Abid, Y. Li, C. Anthony, and A. De Benedetti Translational Regulation of Ribonucleotide Reductase by Eukaryotic Initiation Factor 4E Links Protein Synthesis to the Control of DNA Replication J. Biol. Chem., December 10, 1999; 274(50): 35991 - 35998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-G. Goan, B. Zhou, E. Hu, S. Mi, and Y. Yen Overexpression of Ribonucleotide Reductase as a Mechanism of Resistance to 2,2-Difluorodeoxycytidine in the Human KB Cancer Cell Line Cancer Res., September 1, 1999; 59(17): 4204 - 4207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Wong, M. S. Myette, J. P. Wereley, and C. R. Chitambar Increased Sensitivity of Hydroxyurea-resistant Leukemic Cells to Gemcitabine Clin. Cancer Res., February 1, 1999; 5(2): 439 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Iwasaki, P. Huang, M. J. Keating, and W. Plunkett Differential Incorporation of Ara-C, Gemcitabine, and Fludarabine Into Replicating and Repairing DNA in Proliferating Human Leukemia Cells Blood, July 1, 1997; 90(1): 270 - 278. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
